Less than a week after Clovis Oncology Inc.'s Rubraca became the first PARP inhibitor approved for prostate cancer, AstraZeneca PLC and Merck & Co. Inc.'s class leader Lynparza has become the second, and the one observers expect to dominate the market.
AZ/Merck & Co' s Lynparza Gets US Approval For Prostate Cancer
Days After Green Light For Clovis's Rival PARP
Lynparza has received the green light from the FDA for advanced prostate cancer, its fourth tumor type, and while it may not be the first PARP inhibitor to be approved for this indication, analysts are expecting the drug to lead the class.
More from Anticancer
• By
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.